Brief: Fibrogen Announces Topline Results From Two Late-Stage Pamrevlumab Pancreatic Cancer Studies

Kyntra Bio

30/07/2024 21:23

July 30 (Reuters) - FibroGen Inc  FGEN.O :
    * FIBROGEN ANNOUNCES TOPLINE RESULTS FROM TWO LATE-STAGE
PAMREVLUMAB PANCREATIC CANCER STUDIES AND PROVIDES CORPORATE
UPDATE
    * REDUCE U.S. WORKFORCE BY APPROXIMATELY 75%
    * TERMINATE PAMREVLUMAB RESEARCH AND DEVELOPMENT (RESEARCH
AND
DEVELOPMENT) INVESTMENT AND EXPEDITIOUSLY WIND DOWN REMAINING
OBLIGATIONS
    * STUDY DID NOT MEET PRIMARY ENDPOINT
    * LAPIS STUDY IN LOCALLY ADVANCED, UNRESECTABLE PANCREATIC
CANCER,
SPONSORED BY FIBROGEN, DID NOT MEET PRIMARY ENDPOINT OF OVERALL
SURVIVAL

Source text for Eikon:  ID:nGNX5Xl8qn 
Further company coverage:  FGEN.O 

 ((Reuters.Briefs@thomsonreuters.com;))